EMA Authorised: Obizur (susoctocog alfa) — Baxalta Innovations GmbH

View source ↗

Summary

The European Medicines Agency authorised Obizur (susoctocog alfa) from Baxalta Innovations GmbH for the treatment of Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• OBIZUR (recombinant porcine factor VIII (rpFVIII))

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Baxalta Innovations GmbH. Decision date: 14/08/2025